NOD.Cg-Prkdc^scid
Il2rg^tm1Wjl/SzJ (005557)

Il2rg^tm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (013062) 

NOD.Cg-Rag1^tm1Mom
Il2rg^tm1Wjl/SzJ (007799) 

• Engrafts the widest range of solid and hematological cancers, including ALL and AML
• Most sensitive host for cancer stem cells when compared to NOD scid or nude mice
• Longer lifespan than NOD scid; supports long-term engraftment studies and capabilities; >89 weeks median

• Increased CD4+ FoxP3+ regulatory T cell population
• Enhances human myelopoiesis and terminal differentiation
• Increased efficiency of engrafting human acute myeloid leukemia (AML)

• Long-term multilineage hematopoeitic stem cell repopulation similar to NSG mice
• Engrafts human PBMC without irradiation similar to NSG
• Engrafts a wide range if solid and hematological cancers

• No thymic lymphomas, can be used for long & short-term experiments
• Sensitive to irradiation

• Compromised human stem cell regeneration
• Suppression of human erythropoiesis
• Reduction of human B-lymphopoiesis

Ishikawa et al. 2005;
Shultz et al. 2005

Pearson et al. 2008;
Brehm et al. 2010;
Maykel et al. 2014

NSG-HLA-A2.1 (009617)

NSG-HLA-A2/HHD (014570)

DR1 (012479)

DR4 (017637)

NSG B2m (010636)

NSG-(K^bD^b)^null (023848)

• High engraftment of HLA-A2-restricted immune cells
• Enable functional CD4+ T cell responses to viral infection (014570)

• Useful for transplantation studies in the absence of xeno-GVHD
• Develop allo-GVHD post-engraftmentof DR4-negative CD4+ T cells (017637)

• Resistant to xeno-GVHD (010636)
• Attenuated xeno-GVHD development post-hPBMC transplantation (023848)
• High hCD45+ cell engraftment (023848)
• Useful for studying mechanisms for xeno-GVHD

• No thymic lymphomas - can be used for long-term experiments
• Sensitive to irradiation 

• Reduced CD45+ cell engraftment compared to NSG
• Higher proportion of mice with no CD45+ cell engraftment as compared to NSG (017637)

• Reduced survival post hCD34+ cell transplantation compared to NSG mice (023848)